Table of Contents

company-logo

SciClone Pharmaceuticals (Holdings) Limited, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products in the therapeutic areas of oncology and severe infection in Mainland China and internationally. The company's proprietary product is Zadaxin, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as an immune system enhance. Its in-licensed products include Zometa for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, and hypercalcemia of malignancy; DANYELZA for the treatment of relapsed/refractory high-risk neuroblastoma; and Angiomax, an anticoagulant for use in patients undergoing percutaneous coronary intervention comprising patients with heparin-induced thrombocytopenia and thrombosis syndrome. The company's pipeline products comprise Vibativ, a bactericidal, once-daily, injectable lipoglycopeptide antibiotic for the treatment of adult patients with hospital-acquired and ventilator associated bacterial pneumonia; Omburtamab for the treatment of CNS/ leptomeningeal metastasis from neuroblastoma; RRx-001, a small molecule immunotherapeutic which treats solid tumors; PEN-866, a HSP90-binding miniature drug conjugate; HSP90-PI3K SMDC for the treatment of solid tumors; PT-112 for the treatment of late stage prostate cancer and cholangiocarcinoma; and ABTL-0812 for the treatment of endometrial/lung/pancreatic cancer. The company sells its proprietary, in-licensed, and promotion products through distributors to hospitals and pharmacies. SciClone Pharmaceuticals (Holdings) Limited was founded in 1990 and is headquartered in Shanghai, the People's Republic of China.

SciClone Pharmaceuticals Dividend Announcement

• SciClone Pharmaceuticals announced a annually dividend of HK$0.39 per ordinary share which will be made payable on 2023-06-28. Ex dividend date: 2023-06-02
• SciClone Pharmaceuticals annual dividend for 2023 was HK$0.39
• SciClone Pharmaceuticals's trailing twelve-month (TTM) dividend yield is -%
• SciClone Pharmaceuticals's payout ratio for the trailing twelve months (TTM) is 19.17%

SciClone Pharmaceuticals Dividend History

Ex-Div dateDividend amountDividend typePay date
2023-06-02HK$0.39annually2023-06-28
2022-05-27HK$0.35annually2022-06-22

SciClone Pharmaceuticals Dividend per year

SciClone Pharmaceuticals Dividend Yield

SciClone Pharmaceuticals current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing SciClone Pharmaceuticals stock? Use our calculator to estimate your expected dividend yield:

SciClone Pharmaceuticals Financial Ratios

P/E ratio9.90
PEG ratio0.11
P/B ratio3.40
ROE36.91%
Payout ratio19.17%
Current ratio4.94
Quick ratio4.43
Cash Ratio2.59

SciClone Pharmaceuticals Dividend FAQ

Does SciClone Pharmaceuticals stock pay dividends?
SciClone Pharmaceuticals does not currently pay dividends to its shareholders.
Has SciClone Pharmaceuticals ever paid a dividend?
No, SciClone Pharmaceuticals has no a history of paying dividends to its shareholders. SciClone Pharmaceuticals is not known for its dividend payments.
Why doesn't SciClone Pharmaceuticals pay dividends?
There are several potential reasons why SciClone Pharmaceuticals would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will SciClone Pharmaceuticals ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While SciClone Pharmaceuticals has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is SciClone Pharmaceuticals a dividend aristocrat?
SciClone Pharmaceuticals is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is SciClone Pharmaceuticals a dividend king?
SciClone Pharmaceuticals is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is SciClone Pharmaceuticals a dividend stock?
No, SciClone Pharmaceuticals is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy SciClone Pharmaceuticals stocks?
To buy SciClone Pharmaceuticals you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy SciClone Pharmaceuticals stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.